Physician profile
Thomas Koch
NPI 1871570127
$5,892.84
in general payments reported to CMS, 2019-2025
28 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $90.30 · 2021: $418 · 2022: $788 · 2023: $870 · 2024: $1,949 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,635 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,635.16 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $951.47 | 2019-2025 | |
| Neurent Medical Limited | $817.22 | 2022-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Regeneron Healthcare Solutions, INC. | $591.48 | 2021-2025 | Dupixent, Libtayo |
| Csl Behring | $499.90 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $344.58 | 2019-2025 | |
| Medtronic, INC. | $320.69 | 2021-2025 | Nim Vital |
| Takeda Pharmaceuticals U.S.A., INC. | $317.12 | 2024-2025 | Cuvitru |
| Glaxosmithkline, LLC. | $306.88 | 2021-2025 | Nucala, Trelegy Ellipta |
| Biocryst US Sales Co., LLC | $279.85 | 2023-2025 | Orladeyo |
| Astrazeneca Pharmaceuticals LP | $241.65 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Amgen INC. | $156.39 | 2021-2025 | Tezspire |
| Aerin Medical INC. | $126.30 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $125.76 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $108.33 | 2024 | |
| Genentech USA, INC. | $92.30 | 2023-2025 | Xolair |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $90.86 | 2023-2025 | Xembify |
| Biofire Diagnostics, LLC | $88.20 | 2019-2020 | |
| Stryker Corporation | $84.42 | 2019 | |
| Kaleo, INC. | $67.44 | 2021-2023 | Auvi-Q |
| Alk-Abello, INC | $56.56 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Novartis Pharmaceuticals Corporation | $44.28 | 2024 | |
| Acclarent, INC | $37.94 | 2020 | |
| Bio Products Laboratory USA, INC. | $27.72 | 2022-2023 | Gammaplex, Coagadex |
| Merck Sharp & Dohme LLC | $26.60 | 2021-2025 | Keytruda |
| Intersect Ent, INC. | $26.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.48 | 2023 | Spiriva Respimat |
| Pharming Healthcare, INC. | $19.45 | 2022 | |
| Hikma Pharmaceuticals USA | $17.38 | 2023 | Ryaltris, Mitigare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.